Since 2014
Venous tromboembolism treatment: budget impact analysis of rivaroxaban in Italy
Farmeconomia
View Archive Info| Field | Value | |
| Title |
Venous tromboembolism treatment: budget impact analysis of rivaroxaban in Italy
|
|
| Creator |
Roggeri, Daniela Paola
Roggeri, Alessandro Pengo, Vittorio |
|
| Subject |
—
Venous Thromboembolism; Deep Venous Thrombosis; Pulmonary Embolism; Rivaroxaban |
|
| Description |
BACKGROUND: Venous thromboembolism (VTE) is frequently leading to severe complications, particularly deep vein thrombosis (DVT) and pulmonary embolism (PE), and requires high cost healthcare intevention. Rivaroxaban, a novel oral factor Xa inhibitor approved for treatment of DVT, PE and reduction of the risk of recurrence, may represent a cost‑effective anticoagulant choice.OBJECTIVE: This study aims to evaluate the economic impact of the use of rivaroxaban for preventing DVT and PE in Italy.METHODS: We conducted a budget impact analysis to estimate clinical outcomes and economic consequences associated to rivaroxaban vs. standard therapy (low molecular weight heparin + vitamin K antagonists) in the prevention of DVT and PE, over a three‑year time horizon. In the analysis we performed two hypothesis: complete replacement of LMWH/VKA with rivaroxaban (hypothesis 1) and partial and progressive replacement of LMWH/VKA in the first three years of reimbursement (hypothesis 2). Only direct healthcare costs have been considered.RESULTS: Total replacement of LMWH/VKA with rivaroxaban in DVT and PE is associated to a reduction of recurrent symptomatic thromboembolism, major bleeding, vascular events and mortality, with an expenditure saving of about € 11.3 mln (DVT) and € 6.6 mln (PE), corresponding to an average savings per patient treated with rivaroxaban amounted to € 112.9 and € 123,3, respectively. In hypothesis 2 it is estimated that 22%, 25%, and 27% of DVT patients and 12%, 16%, and 20% of PE patients, would be treated with rivaroxaban over the first three years. This would translate into a total saving on healthcare expenditure of € 8.4 mln for DVT and € 3.2 mln for PE and reduction of length of stay with a slight increase in pharmaceutical expenditure.CONCLUSIONS: Rivaroxaban provides significant advantages in terms of events avoided and related costs that would result in a reduction in the total expenditure on the Italian NHS.
|
|
| Publisher |
SEEd
|
|
| Contributor |
—
|
|
| Date |
2014-12-22
|
|
| Type |
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion — |
|
| Format |
text/html
application/pdf |
|
| Identifier |
http://journals.edizioniseed.it/index.php/FE/article/view/968
10.7175/fe.v15i4.968 |
|
| Source |
Farmeconomia. Health economics and therapeutic pathways; Vol 15, No 4 (2014); 113-127
2240-256X 1721-6915 |
|
| Language |
eng
|
|
| Relation |
http://journals.edizioniseed.it/index.php/FE/article/view/968/1186
http://journals.edizioniseed.it/index.php/FE/article/view/968/1187 |
|
| Coverage |
—
— — |
|